Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;111(4):125-135.
doi: 10.1177/0141076818766725.

Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review

Joanna Prentice  1 , Tarik Amer  1   2 , Ali Tasleem  3 , Omar Aboumarzouk  1   2   4
Affiliations
Review

Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review

Joanna Prentice et al. J R Soc Med. 2018 Apr.

Abstract

Over the last thirty years, the management of Malignant Ureteric Obstruction (MUO) has evolved from a single disciplinary decision to a multi-disciplinary approach. Careful consideration must be given to the risks and benefits of decompression of hydronephrosis for an individual patient. There is a lack of consensus of opinion as well as strong evidence to support the decision process. Outcomes that were identified amongst patients undergoing treatment for MUO included prognosis, quality of life (QOL), complications, morbidity and prognostication tools. A total of 63 papers were included. Median survival was 6.4 months in the 53 papers that stated this outcome. Significant predictors to poor outcomes included low serum albumin, hyponatremia, the number of malignancy related events, and performance status of 2 or worse on the European cooperative cancer group. We propose a multi-centre review of outcomes to enable evidence-based consultations for patients and their families.

Keywords: Clinical; end of life decisions (palliative care); oncology; palliative care; urological cancer; urology.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow chart.
See this image and copyright information in PMC

References

    1. Radecka E, Magnusson M, Magnusson A. Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. Acta Radiol 2006; 47: 328–331. - PubMed
    1. Pradhan TS, Duan H, Katsoulakis E, Salame G, Lee Y-C, Abulafia O. Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer. Int J Gynecol Cancer 2011; 21: 1091–1096. - PubMed
    1. Migita K, Watanabe A, Samma S, Ohyama T, Ishikawa H, Kagebayashi Y. Clinical outcome and management of ureteral obstruction secondary to gastric cancer. World J Surg 2011; 35: 1035–1041. - PubMed
    1. Meyer JE, Yatsuhashi M, Green THJ. Palliative urinary diversion in patients with advanced pelvic malignancy. Cancer 1980; 45: 2698–2701. - PubMed
    1. Sountoulides P, Pardalidis N, Sofikitis N. Endourologic management of malignant ureteral obstruction: indications, results, and quality-of-life issues. J Endourol 2010; 24: 129–142. - PubMed